1. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807-815.
2. Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, et al. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? Cells. 2021;10(5):1203.
3. Vagapova ER, Lebedev TD, Prassolov VS. Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis. Sci Rep. 2021;11(1):11234.
4. John AE, Joseph C, Jenkins G, Tatler AL. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021 May 24.
5. Falleni M, Tosi D, Savi F, Chiumello D, Bulfamante G. Endothelial-Mesenchymal Transition in COVID-19 lung lesions. Pathol Res Pract. 2021;221:153419.
6. Kiener M, Roldan N, Machahua C, Sengupta A, Geiser T, et al. Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. Front Med (Lausanne). 2021;8:644678.
7. Yim J, Lim HH, Kwon Y. COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. Arch Pharm Res. 2021;44(5):499-513.
8. McGroder CF, Zhang D, Choudhury MA, Salvatore MM, D'Souza BM, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax. 2021:2021-217031.
9. Mishra M, Sindhwani G. Antifibrotics for COVID-19 related lung fibrosis: Agents with benefits? Adv Respir Med. 2021;89(2):231-233.
Kayarat B, Khanna P, Sarkar S. 10.1038/nrd.2017.170
10. Kayarat B, Khanna P, Sarkar S. Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management. Indian J Crit Care Med. 2021 Feb;25(2):242-244. doi: 10.5005/jp-journals-10071-23733. PMID: 33707912; PMCID: PMC7922461.
11. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
12. Woodcock HV, Eley JD, Guillotin D, Platé M, Nanthakumar CB, Martufi M, et al. The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nat Commun. 2019;10(1):6.
13. Mora AL, Rojas M, Pardo A, Selman M. BG. Nat Rev Drug Discov. 2017;16(11):810.
14. Raghu G, Van Den Blink B, Hamblin MJ, Whitney Brown A, Golden JA, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis a randomized clinical trial. JAMA. 2018;319(22):2299–307.